×
Resources » Webinars
Email to GenScript

2016 Webinar Series

Our webinar series features 30-45 minute, online seminars followed by 15 minute question and answer periods, which are specially designed to highlight strategies, techniques, services, and products that can streamline your research and help you avoid common pitfalls in your experimental designs.

Can't attend? Register anyway and you will receive a link to the recording after the live session.


Click a title below to jump to the full webinar abstract


Title Register
Characterization of the host antibody responses against anti-HIV/SIV antibodies delivered with AAV
October 6, 2016/
2:00 PM EST
October 20, 2016/
2:00 PM EST
CRISPR solutions: how to choose and implement CRISPR in your research
October 11, 2016/
9:00 AM EST
Or 2:00 PM EST
Hybridoma generation for therapeutic antibody drug discovery and applications
October 18, 2016/
9:00 AM EST
Or 2:00 PM EST
Cancer immunotherapy: advancing and accelerating immuno-oncology research and development
October 25, 2016/
2:00 PM EST
Plant biology: pitfalls and solutions to frequently used research techniques
November 3, 2016/
9:00 AM EST
Or 2:00 PM EST
Objective quantitative evaluation of anti-fibrotic agents in animal models
November 10, 2016/
9:00 AM EST
Or 2:00 PM EST
The role of LC-MS in antibody drug discovery
November 16, 2016/
9:00 AM EST


Characterization of the host antibody responses against anti-HIV/SIV antibodies delivered with AAV

Long-term delivery of neutralizing antibodies by means of recombinant adeno-associated virus (rAAV) is a novel and promising approach for the prevention or treatment of HIV infection since it circumvents the difficulties of generating a successful immunogen or vaccine. It is also cost-efficient: one single injection accounts for long-term expression (years) of the desired antibody or antibodies. However, host antibodies raised against the delivered protein are a serious concern that could compromise the efficacy of this approach by reducing the concentration and functionality of the delivered antibody. A better understanding of how anti-antibody responses arise is crucial to make this a reliable approach. In this webinar we will describe the dynamics and characteristics of the anti-antibody responses in macaques that received either a combination of anti-HIV antibodies (10-1074, 10E8 and 3BNC117 or 1NC9, 8ANC195 and 3BNC117) in therapy trials or anti-SIV antibodies in prevention trials. Overlapping peptide screening (Pepscans) demonstrated generation of anti-idiotypic antibodies. A correlation was found between the level of divergence of the delivered antibody from germline and the magnitude of the host response. Our results indicate that the problem of anti-anti responses will need to be overcome for the promise of this AAV antibody-delivery strategy to be effectively realized.

Presented by: Jose Martinez-Navio, Assistant Scientist, University
of Miami – Miller School of Medicine
 

October 6, 2016

October 20, 2016

CRISPR solutions: how to choose and implement CRISPR in your research

Named the 2015 breakthrough of the year, the CRISPR technology has quickly become one of the most popular gene editing technologies. However, as the technology advances, so do the number of reagents and tools available, which can make selection of the most appropriate system for the intended research application trickier. In this webinar, we will discuss the different CRISPR technology systems on the market, from CRISPR plasmids to RNA oligos and screening libraries. We will describe the advantages, disadvantages, and important considerations prior to starting your CRISPR experiments. We will also go over helpful workflows to ensure your gene editing projects go smoothly.

  Presented by: Laura Geuss, PhD., Sr. Marketing Specialist, GenScript
And William Tan, Ph.D., Technical Writer/Marketing Specialist, GenScript

 

October 11, 2016

 
Register 2:00 PM EST

Hybridoma generation for therapeutic antibody drug discovery and applications

Therapeutic antibody drugs have recently experienced explosive growth. Within oncology research alone, 14 therapeutic antibody drugs received FDA approval for new treatments or indications during 2015. Additionally, more than 300 therapeutic antibody drugs are in ongoing clinical trials. Driven by the increase in biomarker discovery, more and more therapeutic antibody drugs are set to enter the market with increased competition. Therefore, to maximize the success of therapeutic antibody drug development, it is essential to thoroughly vet antibody drug candidates at every step of the process. This webinar will review the current platforms for generating antibodies and discuss the screening and characterization technologies required for rational selection of lead therapeutic antibody drug candidates. We will examine key case studies demonstrating appropriate use of cutting edge high throughput screening platforms to guide hybridoma clone selection. Ultimately, attendees will understand how these approaches integrate with both upstream and downstream therapeutic antibody drug discovery methodologies.

Presented by: Liusong Yin , PhD, Senior Scientist, GenScript
 

October 18, 2016

 
Register 2:00 PM EST

Cancer immunotherapy: advancing and accelerating immuno-oncology research and development

Cancer immunotherapy has emerged as an exciting new approach to cancer treatment because of its specificity, adaptability and durability. The discovery of immune targets and development of therapeutic antibodies against immune checkpoints is becoming the momentum among academia and pharmaceutical industry. With the increasing success and subsequent interests in cancer immunotherapy, there is a growing need for well-characterized cell models, antibodies and proteins for immune-oncology. If you are interested in this rising field, or want to advance and accelerate your immune-oncology research, please join this webinar. We will introduce the development, application and challenges in Cancer immunotherapy field, and the one-stop station including diversity functional antibodies, targets, cell models and assay platforms from GenScript to accelerate the related discovery and development program.

Presented by: Amy Mendenhall, Ph.D., Technical Marketing Specialist, Genscript
 

October 25, 2016

Plant biology: pitfalls and solutions to frequently used research techniques

With the different challenges facing researchers in Plant Biology, it is important to identify any possible complications early to minimize the number of repeats needed for certain frequently used experiments and techniques. Commonly used techniques in plant biology include fluorescence microscopy, mass spectrometry/posttranslational studies, plant growth assays, and immunoprecipitation/co-immunoprecipitation. Long life cycles and variable growth conditions can often make workable materials for these experiments scarce in quantity. Any kind of unintentional repeat could set experimental timelines back anywhere from weeks to months, depending on the plant being used. We will introduce the various challenges faced when using these techniques for plant biology purposes, followed by some solutions and tips to consider before implementing these techniques in your research workflow. Lastly, we will also introduce the various tools available from GenScript to help counter these issues as well.

Presented by: David Lin, Technical Writer/Marketing Specialist, GenScript
 

November 3, 2016

 
Register 2:00 PM EST

Objective quantitative evaluation of anti-fibrotic agents in animal models

Fibrosis is becoming a leading cause of death in organ injuries, particularly among aging population, without effective and safe therapies to date. One of the major hurdles in fibrosis-related drug discovery is the dependence on manual scoring for therapeutic effects of lead compounds in animal models. Here we introduce a service of animal models coupled to a digital imaging and quantitation method. The method incorporated nonlinear microscopy by second harmonic generation to produce collagen-specific images, and by two-photon excitation fluorescence to delineate tissue morphology. The imaging and subsequent analysis were validated with fibrotic diseases in liver, kidney, lung, bone marrow, and other organs, using reference compounds including Imatinib, Nintedanib, and Pirfenidone. The therapeutic effects of the compounds observed in our models were definitive and reproducible. The results correlated well with those of parallel biomarker analysis. The method is straightforward and stain-free. It provides further histological detail of disease status. We present this method as revolution in histological evaluation of anti-fibrosis drugs in pre-clinical settings.

Presented by: Bertha Xue, Ph.D., Senior Scientist of Pharmacology Department at Discovery Biology, GenScript.
 

November 10, 2016

 
Register 2:00 PM EST

The role of LC-MS in antibody drug discovery

There are many analytical methods developed for antibody characterization, including various HPLC methods, analytical ultracentrifugation, MS, DSC and others. Among these techniques, Liquid Chromatography combined with Mass Spectrometry (LC-MS) is a proven analytical technique of choice, used in the various stages of antibody drug discovery and development. But what exactly is LC-MS and why is it so popular? In this webinar, we will review the basics of LC-MS and take a closer look at the analysis capabilities of this versatile technique. We will review how the LC-MS platform at GenScript allows our scientists to develop a deeper understanding of the Antibody drug structure, including disulfide linkages, post-translational modifications, N-linked glycans and more. We will also look at strategies for optimizing the use of this technique, along with potential pitfalls and solutions.

Presented by: Rui Wang, Ph.D, Senior Scientist, GenScript
 

November 16, 2016

Click on a webinar title below to watch the webinar and download a pdf of the presentation

 
*
*
*
*